Fig. 6.

A model of the systemic and local PD-L1 sources in patients with advanced NSCLC. The PD-L1 sources that we have associated with the clinical outcome of patients with advanced NSCLC treated with anti-PD-(L)1 blockade agents are highlighted with color squares. We found that higher percentages of PD-L1 + monocytes were associated with longer PFS and OS, higher percentages of PD-L1 + neutrophils, PLTs, and PMPs with PFS, and higher percentages of PD-L1 + tumor cells with OS. Figure created with Biorender.com